from web site

Scler. 2004; 10( 4 ):434 -441. View abstract. Wade, D. T., Robson, P., Home, H., Makela, P., and Aram, J. An initial regulated research study to identify whether whole-plant marijuana extracts can enhance intractable neurogenic signs. Clin. Rehabil. 2003; 17( 1 ):21 -29. View abstract. Watzl, B., Scuderi, P., and Watson, R. R. Marijuana elements stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro.
1991; 13( 8 ):1091 -1097. View abstract. Aviello G, Romano B, Borrelli F, et al. Chemopreventive impact of the non-psychotropic phytocannabinoid cannabidiol on speculative colon cancer. J Mol Medication (Berl) 2012; 90( 8 ):925 -34. View abstract. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety caused by simulated public speaking in treatment-nave social fear patients.
View abstract. Bisogno T, Di Marzo Y. The function of the endocannabinoid system in Alzheimer's disease: truths and hypotheses. Curr Pharm Des 2008; 14( 23 ):2299 -3305. View abstract. Booz GW. Cannabidiol as an emerging healing method for minimizing the effect of inflammation on oxidative tension. Free Radic Biol Med 2011; 51( 5 ):1054 -61. View abstract. Bornheim LM, Everhart ET, Li J, Correia MA.
Biochem Pharmacol 1993; 45( 6 ):1323 -31. View abstract. Brady CM, Das, Gupta R, Dalton C, et al. An open-label research study of cannabis-based extracts for bladder dysfuntion in innovative several sclerosis. Mult Scler 2004; 10( 4 ):425 -33. View abstract. Campos A/C, Moreira FA, Gomes FV, et al. Numerous systems associated with the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

View abstract. Cannabidiol Now Showing Up In Dietary Supplements. Natural Medicines Website. Readily Additional Info at: Accessed: May 31, 2015. Carroll CB, Bain PG, Teare L, et al. Marijuana for dyskinesia in Parkinson disease: a randomized double-blind crossover research study. Neurology 2004; 63( 7 ):1245 -50. View abstract. Consroe P, Sandyk R, Snider SR. Open label examination of cannabidiol in dystonic movement disorders.
View abstract. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic results of cannabidiol (CBD) in generalized social anxiety disorder: an initial report. J Psychopharmacol 2011; 25( 1 ):121 -30. View abstract. Dalterio S, Steger R, Mayfield D, Bartke A. Early cannabinoid direct exposure influences neuroendocrine and reproductive functions in mice: II.

Pharmacol Biochem Behav 1984; 20( 1 ):115 -23. View abstract. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and possible therapeutic function in epilepsy and other neuropsychiatric conditions. Epilepsia 2014; 55( 6 ):791 -802. View abstract. Englund A, Morrison PD, Nottage J, et al. Cannabidiol hinders THC-elicited paranoid signs and hippocampal-dependent memory impairment. J Psychopharmacol 2013; 27( 1 ):19 -27.